E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

PHASE3CompletedINTERVENTIONAL
Enrollment

1,276

Participants

Timeline

Start Date

September 20, 2006

Primary Completion Date

March 12, 2012

Study Completion Date

December 11, 2017

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Eribulin Mesylate

1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days

DRUG

Capecitabine

Capecitabine 2.5 g/m\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days

Trial Locations (169)

1000

Institut Jules Bordet, Medical Oncology Unit, Brussels

1898

La Plata

2077

Hornsby

2199

Sandton

3065

Saint Vincent's Hospital, Fitzroy

4091

Mayville

Durban

5035

Ashford Cancer Centre, Adelaide

5700

Gyula

6000

Royal Perth Hospital, Perth

7000

Royal Hobart Hospital, Hobart

9000

Algemeen Ziekenhuis Sint Lucas, Ghent

9300

OLVZ Aalst, Oncology Service, Aalst

10825

Spitalul Militar Central Bucuresti, Bucharest

115478

Blokhin Cancer Research Centre, Moscow

150054

Regional Oncology Dispensary, Yaroslavl

400015

Cluj-Napoca

700106

Centrul de Oncologie Medicala, Iași

Unknown

Anaheim

La Verne

Poway

Centralia

Augusta

Boston

Jefferson City

Lebanon

Ephrata

Cookeville

Germantown

Amarillo

Wenatchee

Instituto Argentino de Diagnostico y Tratamiento, Cuidad Autonoma de Buenos Aires

La Plata

Corporacion Medica General San Martin, San Martín

Hospital Italiano de Buenos Aires, Buenos Aires

Buenos Aires

Ciudad Autonoma

Mendoza

Bankstown Hospital, Oncology Trials Unit, Bankstown

Liverpool Hospital, Cancer Therapy Centre, Liverpool

Epworth Freemasons Hospital, East Melbourne

Sir Charles Gairdner Hospital, Dept. of Medical Oncology, Nedlands

Mater Adult Hospital, South Brisbane

Centre Hosptialier Universitaire Sart Tilman Liege, Liège

Florianópolis

Associacao Hospital de Caridade Ijui, Ijuí

Instituto de Oncologia Ltda, Jundiaí

Proonco Centro de Tratamento Oncologico, Londrina

Hospital de Clinicas de Porto Alegre, Servicio de Oncologia, Porto Alegre

Hospital Nossa Senhora da Conceicao, Porto Alegre

Servico de Quimioterapia de Pernambuco-SEQUIPE, Recife

Instituto Ribeiraopretano de Combate ao Cancer, Ribeirão Preto

Nucleo de Oncologia da Bahia, Salvador

Faculdade de Medicina do ABC, Santo André

Grupo Paulista de Oncologia Integrada Ltda, São Paulo

Hospital das Clinicas de Faculdade de Medicina da Universidade de Sao, São Paulo

Hospital do Cancer de Sao Paulo-AC Camargo, São Paulo

Hospital do Cancer de Sao Paulo-AC. Camargo, São Paulo

Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo

Burgas

Gabrovo

Pleven

Plovdiv

Rousse

Shumen

Sofia

Stara Zagora

Varna

Kingston

Centre Hospitalier Universitaire de Montreal, Hopital Notre Dame, Montreal

Thunder Bay Regional Health Science Centre Northwestern Ontario, Thunder Bay

Nemocnice Ceske Budejovice, a.s., České Budějovice

Onkologicka Klinika, Fakutni Nemocnice, Olomouc

1. LF UK, Ustav radiacnej onkologie, Prague

Krajska nemocnice T. Bati, Zlin Poiters

Centre Hospitalier La Roche sur Yon, CHD les Oudairies, La Roche-sur-Yon

CHU de Poitiers, Service d'Oncologie Medicale, Poitiers

Hopital Nord Saint-Etienne, Saint-Priest-en-Jarez

Augusta-Kranken-Anstalt, Klinik fur Hamatologie und Onkologie, Bochum

Hamburg

Homburg

Universitatsfrauenklinik Magdeburg, Magdeburg

Rostock

Pátrai

Gyor

Debrecen University, Debrecen

Debrecen

Pecsi Tudomanyegyetem, Onkoterapias Intezet, Pécs

Szeged

Veszprém

Barzilai Medical Center, Ashkelon

Soroka Medical Center, Beersheba

Sharet Institute of Oncology, Jerusalem

Meir Hospital, Sapir Medical Center, Kfar Saba

Rabin Medical Center, Petah Tikva

Kaplan Medical Center, Rehovot

The Chaim Sheba Medical Center, Tel Litwinsky

Ancona

Unita Operativa de Oncologia, Lugo

Meldola

Modena

Azienda Ospedaliera San Salvatore, Pesaro

Ospedale Civile S. Maria delle Croci, Ravenna

UO di Onco-ematologia, Rimini

Sassari

Centro Estatal de Cancerologia, Chihuahua City

Monterrey

Consultorio del Dr. Trigueros, Morelia

Regionalny Osrodek Onkologii, Bialystok

Bytom

Elblag

Krakow

Torun

Bucharest

Cluj-Napoca

Spitalul Clinic Judetean Sibiu, Sibiu

Timișoara

Barnaul

Kazan'

Kirov

Krasnodar

Moscow

Nizhny Novgorod

Obninsk

Rostov-on-Don

Saint Petersburg

Saratov

Sochi

Tomsk

Vladimir

Singapore

Pretoria

Groenkloof

Panorama Medical Centre, Cape Town

Johannesburg

Barakaldo

A Coruña

Barcelona

Guadalajara

Seville

Valencia

Changhua

Taichung

Tainan City

Taipei

Yung-Kang City

Chernihiv

Dnipro

Donetsk

Kharkiv

Khmelnytskyi

Kiev

Kryvyi Rih

Kyiv

Lviv

Odesa

C1406FWY

Hospital General de Agudos Teodoro Alvarez, Ciudad Autonoma

B1629AHJ

Pilar

S2000DSK

Rosario

T4000IAK

San Miguel de Tucumán

Bema 8000

Bahía Blanca

C1280AEB

Buenos Aires

S3000FFU

Santa Fe

H3G 1A4

Montreal General Hospital, Montreal

H4J 1C5

Hopital du Sacre-Coeur de Montreal, Montreal

80-210

Wojewodzkie Centrum Onkologii, Gdansk

10-513

Olsztyn

44-200

Rybnik

51-124

Wojewodzki Szpital Specjalistyczny, Wroclaw

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00337103 - E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | Biotech Hunter | Biotech Hunter